Myasthenia Gravis Thymus: Complement Vulnerability of Epithelial and Myoid Cells, Complement Attack on Them, and Correlations with Autoantibody Status
- 30 September 2007
- journal article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 171 (3), 893-905
- https://doi.org/10.2353/ajpath.2007.070240
Abstract
In early-onset myasthenia gravis, the thymus contains lymph node-type infiltrates with frequent acetylcholine receptor (AChR)-specific germinal centers. Our recent evidence/two-step hypothesis implicates hyperplastic medullary thymic epithelial cells (expressing isolated AChR subunits) in provoking infiltration and thymic myoid cells (with intact AChR) in germinal center formation. To test this, we screened for complement attack in a wide range of typical generalized myasthenia patients. Regardless of the exact serology, thymi with sizeable infiltrates unexpectedly showed patchy up-regulation of both C5a receptor and terminal complement regulator CD59 on hyperplastic epithelial cells. These latter also showed deposits of activated C3b complement component, which appeared even heavier on infiltrating B cells, macrophages, and especially follicular dendritic cells. Myoid cells appeared particularly vulnerable to complement; few expressed the early complement regulators CD55, CD46, or CR1, and none were detectably CD59(+). Indeed, when exposed to infiltrates, and especially to germinal centers, myoid cells frequently labeled for C1q, C3b (25 to 48%), or even the terminal C9, with some showing obvious damage. This early/persistent complement attack on both epithelial and myoid cells strongly supports our hypothesis, especially implicating exposed myoid cells in germinal center formation/autoantibody diversification. Remarkably, the similar changes place many apparent AChR-seronegative patients in the same spectrum as the AChR-seropositive patients.Keywords
This publication has 61 references indexed in Scilit:
- Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myastheniaExperimental Neurology, 2006
- Clinical and serological study of myasthenia gravis in HuBei Province, ChinaJournal of Neurology, Neurosurgery & Psychiatry, 2006
- The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in miceClinical and Experimental Immunology, 2006
- Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjectsImmunology, 2005
- Analysis of the human thymic perivascular space during agingJCI Insight, 1999
- Germinal CentersAnnual Review of Immunology, 1994
- Protection of germinal centres from complement attack: Decay‐accelerating factor (DAF) is a constitutive protein on follicular dendritic cells. A study in reactive and neoplastic folliclesThe Journal of Pathology, 1993
- Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus.JCI Insight, 1992
- Functional Activities of Autoantibodies to Acetylcholine Receptors and the Clinical Severity of Myasthenia GravisNew England Journal of Medicine, 1982
- THE PATHOLOGY OF THE THYMUS IN MYASTHENIA GRAVISMedicine, 1949